Document Report Card
Basic Information
ID: ALA3603812
Journal: Bioorg Med Chem Lett
Title: Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease.
Authors: Zhang J, Romero J, Chan A, Goss J, Stucka S, Cross J, Chamberlain B, Varoglu M, Chandonnet H, Ryan D, Lippa B.
Abstract: Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.
CiteXplore: 26117562